ArticleFrontiers in immunology2026
Insufficient mycophenolate mofetil maintenance dosage increases the relapse risk in neuromyelitis optica spectrum disorders.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The utilization of biologic agents for neuromyelitis optica spectrum disorders (NMOSD) is constrained by high cost and limited accessibility in China. While clinical guidelines recommend mycophenolate mofetil (MMF) for relapse prevention, the factors influencing its therapeutic efficacy remain poorly characterized. This study aimed to investigate clinical predictors of relapse in patients with NMOSD treated with MMF, specifically evaluating the impact of MMF maintenance dosage and concurrent corticosteroid therapy on relapse prevention. Methods: In this retrospective cohort study, clinical data were collected from NMOSD patients consecutively treated with MMF at the Departments of Neurology of the First Affiliated Hospital of Soochow University and the Second Affiliated Hospital of Anhui Medical University. Patients were categorized into three groups based on their maintenance dosage: low-dose (≤ 750 mg/d), medium-dose (= 1000 mg/d), and high-dose (≥ 1250 mg/d). The primary endpoint was the first relapse during treatment. Kaplan-Meier analysis was employed to compare relapse-free survival rates among groups, and Cox proportional hazards regression models were utilized to identify factors associated with relapse during follow-up. Results: A total of 82 NMOSD patients were included (34 males and 48 females), with a mean age of 43.6 ± 15.9 years. During the median follow-up time of 27.7 months, 39 patients (47.6%) experienced relapse. Kaplan-Meier analysis demonstrated that the relapse-free survival rate in the high-dose group was significantly higher than that in the medium-dose group and the low-dose group (log-rank test, Conclusion: Suboptimal MMF maintenance dosing (≤ 1000 mg/d) significantly increases the risk of relapse in patients with NMOSD. A high-dose regimen (≥ 1250 mg/d) and concurrent corticosteroid administration, if well-tolerated, represent key strategies to mitigate relapse risk during MMF treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.